MOTORK
15.11.2021 08:32:10 CET | Business Wire | Press release
MotorK, plc (AMS: MTRK) (“MotorK” or “the Group"), a leading SaaS provider for the automotive retail industry in the EMEA region, today reported financial results for the third quarter ended September 30, 2021.
Third Quarter 2021 and Other Recent Financial and Operating Highlights:
- Revenue of €8.1 million in Q3 2021, up 86% compared to Q3 2020;
- Revenue of €20.9 million for the first 9 months of 2021, up 54% compared to the same period in 2020;
- Adjusted EBITDA was €1.4 million in Q3 2021, representing an adjusted EBITDA margin of 17.5%;
- Adjusted EBITDA was €1.8 million for the first 9 months of 2021, representing an adjusted EBITDA margin of 8.6%;
- Revenue and adjusted EBITDA growth driven by the strong performance of SaaS platform revenue in 2021 YTD, which was up 73% year-on-year;
- Total R&D spend reached €2.0 million in Q3 2021, up 53% compared to €1.3 million R&D spend in Q3 2020, leading to a total of €5.4 million, or 26% of the revenue, for the first 9 months of 2021;
- Revenue for FY 2021 expected to come at the top end of the €25-27m guidance range, in light of current results.
“In the third quarter, MotorK continued to deliver solid top-line growth driven by the strong performance of our cloud-based SaaS platform that offers a comprehensive suite of products to support the full vehicle lifecycle and the entire customer journey,” commented Marco Marlia, CEO of MotorK. “Our business continues to progress at a fast pace, and we are very satisfied with the performance we delivered this quarter. Looking ahead, we will continue to focus on our growth strategy focused on innovation to further strengthen our value proposition and SaaS offering expansion, as evidenced by our healthy level of R&D investment which was up significantly compared to the prior year. We will also continue to actively identify and leverage organic and inorganic opportunities to win new customers and roll-out additional offerings into new markets and geographies.”
FINANCIAL HIGHLIGHTS
Key Figures
Key figures |
Q3 '21 |
Q3 '20 |
y.o.y.
|
YTD '21 |
YTD '20 |
y.o.y.
|
||||||
€'000 |
||||||||||||
Revenue |
8,089 |
4,359 |
86% |
20,870 |
13,547 |
54% |
||||||
Adjusted EBITDA* |
1,411 |
(212) |
- |
1,749 |
(1,415) |
- |
||||||
Adjusted EBITDA margin |
17.5% |
-5% |
22% |
8% |
-10% |
19% |
*Adjusted EBITDA is defined as EBITDA as adjusted for stock option costs and certain income and costs, which are expected to occur infrequently, and that management considers not reflective of ongoing operational activities. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenue.
The Group generated €8.1 million in revenue for the quarter, up 86% compared to the prior year, driven by a strong performance of its SaaS platform, across both the WebSparK and LeadSparK platforms. Revenue this quarter was positively impacted by delivery to a major OEM client in Germany.
Adjusted EBITDA for the quarter was €1.4 million, compared to a €212,000 loss in 2020. The Adjusted EBITDA margin was strong at 17.5%, benefitting from SaaS-driven operating leverage, despite continued investments in R&D and innovation.
Revenue
Revenue by product and service line
The table below shows the Group’s revenue broken down by product and service line for Q3 2021 and Q3 2020, and for the nine-month periods ended September 30, 2021 and September 30, 2020.
Revenue by product and service line |
Q3 '21 |
Q3 '20 |
y.o.y.
|
YTD '21 |
YTD '20 |
y.o.y.
|
||||||
€'000 |
||||||||||||
SaaS platform revenue |
5,738 |
2,364 |
143% |
12,294 |
7,091 |
73% |
||||||
Digital Marketing revenue |
1,799 |
1,591 |
13% |
5,840 |
5,060 |
15% |
||||||
Other revenue |
552 |
404 |
37% |
2,736 |
1,396 |
96% |
||||||
Total |
8,089 |
4,359 |
86% |
20,870 |
13,547 |
54% |
With respect to the product and service lines of the Group’s business, the Group’s revenue is derived primarily from its SaaS platform. Revenue generated from the SaaS platform amounted to €5.7 million in the third quarter of 2021, an increase of about €3.3 million or 143% compared to the prior year period, and €12.3 million for the nine-month period ended September 30, 2021, an increase of about €5.2 million, or 73%, compared to the nine-month period ended September 30, 2020.
Research & Development Costs and Investments
Set forth below are the breakdown of the Group’s total R&D spend in absolute terms and as a percentage of the Group’s total revenue for Q3 2021 and Q3 2020, and for the nine-month periods ended September 30, 2021 and September 30, 2020.
R&D spend |
Q3 ‘21 |
Q3 ‘20 |
y.o.y.
|
YTD ‘21 |
YTD ‘20 |
y.o.y.
|
|||||||
€’000 (except percentages) |
|||||||||||||
Total R&D spend |
2,026 |
1,320 |
54% |
5,351 |
3,688 |
45% |
|||||||
- of which capitalised |
(800) |
(689) |
16% |
(2,210) |
(1,996) |
11% |
|||||||
- of which expensed in the income statement |
1,226 |
631 |
94% |
3,141 |
1,692 |
86% |
|||||||
Total R&D spend as a percentage of Group total Revenue |
25% |
30% |
-5% |
26% |
27% |
-2% |
|||||||
As part of its growth strategy, MotorK has continued to invest in R&D to develop innovative solutions for its customers and expand the capabilities of its SaaS platform. R&D spend reached €2 million in Q3 2021 and €5.4 million for the first 9 months of 2021, up 54% and 45% respectively compared to the same periods in 2020.
OUTLOOK
MotorK expects FY 2021 revenue to come at the top end of the €25-27 million guidance range, in light of current results.
Conference Call Information
Marco Marlia (CEO) and Andrea Servo (CFO) will host a conference call for analysts and investors at 5:00 pm CET to discuss the 2021 third quarter results. A live webcast of the conference call and related earnings materials can be accessed on MotorK’s Investor Relations website (investors.motork.io/). A replay of the webcast will be available through the same link on the website following the conference call.
About MotorK Plc
MotorK (AMS: MTRK) is a leading software as a service (“SaaS”) provider for the automotive retail industry in the EMEA region, with over 300 employees and eight offices in seven countries (Italy, Spain, France, Germany, Portugal, the UK and Israel). MotorK empowers car manufacturers and dealers to improve their customer experience through a broad suite of fully integrated digital products and services. MotorK provides its customers with an innovative combination of digital solutions, SaaS cloud products and the largest R&D department in the automotive digital sales and marketing industry in Europe. MotorK was founded in Italy in 2010 and has been recognised by multiple organisations as one of the fastest growing tech companies in Europe – including Euronext TechShare, Tech Tour 50, Technology Fast 500 EMEA and the FT 1000. For more information, please visit: www.motork.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211114005325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
